Department of Surgery, Lehigh Valley Health Network, 1275 S. Cedar Crest Boulevard, Allentown, PA 18103, USA.
Tech Coloproctol. 2011 Jun;15(2):185-9. doi: 10.1007/s10151-010-0668-y. Epub 2011 Mar 23.
An increasing number of patients are treated with anticoagulation for many medical conditions. Our practice is to suspend warfarin 5-7 days, aspirin 3 days, and clopidogrel (Plavix) 7 days prior to colonoscopy that may require polypectomy. Generally, we accept an INR of ≤1.5 as safe. However, there are no published case series documenting when it is safe to resume these medications after polypectomy. Therefore, the management of anticoagulation after polypectomy varies. We sought to evaluate the safety of our practice with regard to anticoagulation and polypectomy.
We conducted a retrospective review of all patients over the age of 18 who underwent colonoscopy with polypectomy while on anticoagulation for various medical comorbidities at our institution over a 15-month period (July 2007 to September 2008). All morbidity and mortality that occurred for the first 3 weeks post-polypectomy was recorded. The Mann-Whitney test was performed using SPSS 15.5.
From July 2007 to September 2008, we performed 579 colonoscopies with polypectomy on patients who were on anticoagulation therapy during the study period. Seven (1.2%) patients presented to the Emergency Room or were hospitalized within 3 weeks after polypectomy for lower gastrointestinal bleeding. Distribution of anticoagulants was listed: 2 (28.6%) patients on warfarin, 4 (57.1%) on aspirin, and 1 (14.3%) on clopidogrel. Warfarin was held for, on average, 4 days pre-polypectomy and 1 day post-polypectomy. Aspirin was held, on average, 3 days both pre- and post-polypectomy. Clopidogrel was held, on average 6.5 days pre-polypectomy but restarted immediately post-polypectomy. No statistically significant difference was found between the number of days that anticoagulation was held pre- or post-polypectomy in individuals who did and did not bleed.
We found that our practice of resuming anticoagulation or antiplatelet agents (warfarin, aspirin, and clopidogrel) post-polypectomy was safe and did not prove to significantly affect the post-polypectomy rate of hemorrhage.
越来越多的患者因多种医疗状况而接受抗凝治疗。我们的常规做法是在需要进行结肠息肉切除术的结肠镜检查前,停用华法林 5-7 天、阿司匹林 3 天、氯吡格雷(波立维)7 天。一般来说,我们认为 INR 值≤1.5 是安全的。然而,目前尚无发表的病例系列研究记录在结肠息肉切除术后何时可以安全地恢复这些药物。因此,结肠息肉切除术后的抗凝管理存在差异。我们试图评估我们在抗凝和结肠息肉切除术后的实践安全性。
我们对在我院接受各种医疗合并症抗凝治疗的 18 岁以上患者进行了回顾性研究,这些患者在 15 个月的时间内(2007 年 7 月至 2008 年 9 月)接受了结肠镜检查和结肠息肉切除术。记录所有患者在息肉切除术后 3 周内出现的所有并发症和死亡情况。使用 SPSS 15.5 进行 Mann-Whitney 检验。
2007 年 7 月至 2008 年 9 月,我们对研究期间接受抗凝治疗的 579 例接受结肠镜检查和结肠息肉切除术的患者进行了治疗。7(1.2%)例患者在息肉切除术后 3 周内因下消化道出血到急诊室就诊或住院。抗凝药物的分布情况如下:2(28.6%)例患者服用华法林,4(57.1%)例患者服用阿司匹林,1(14.3%)例患者服用氯吡格雷。华法林在息肉切除术前平均停用 4 天,术后停用 1 天。阿司匹林在息肉切除术前和术后平均停用 3 天。氯吡格雷在息肉切除术前平均停用 6.5 天,但在息肉切除术后立即恢复使用。在是否发生出血的患者中,息肉切除术前和术后抗凝药物的停用天数没有统计学差异。
我们发现,我们在结肠息肉切除术后恢复抗凝或抗血小板药物(华法林、阿司匹林和氯吡格雷)的做法是安全的,且不会显著影响息肉切除术后出血的发生率。